Read today’s Kaiser Health News
In other news:
NIH has paused patenting of discoveries, slowing their use in developing treatments:For the past five weeks, employees at NIH technology transfer offices have been barred from filing new patent applications and been restricted from licensing existing ones, according to emails obtained by STAT and interviews with current and former NIH employees.
On Jan. 29, the NIH’s acting director, Matthew Memoli, sent an email to senior agency officials instructing them to pause all technology transfer discussions with outside parties and not negotiate any new agreements.
About hospitals and healthcare systems
748 hospitals at risk of closure, state by state FYI
About pharma
Federal judge stops compounded copies of Eli Lilly weight loss, diabetes drugs: A federal judge has effectively ended the ability of compounding pharmacies to make their own copies of Eli Lilly’s weight loss and diabetes drugs Zepbound and Mounjaro.
In a sealed decision filed late Wednesday, Judge Mark Pittman of the Northern District of Texas declined to issue an injunction to stop the Food and Drug Administration (FDA) from declaring there was no longer a shortage of the medicines’ active ingredient, tirzepatide.
10 Best-Selling Drugs of 2024 Rake in Billions Amid Exclusivity Threats A great review of the topic.